OncLive TV

Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.

Neal Shore, MD, FACS, discusses gaps in prostate cancer management and future research directions that may optimize care for high-risk localized disease.

Toon Van Gorp, MD, PhD, discusses the significance of mirvetuximab soravtansine as treatment for FRα-positive, platinum-resistant ovarian cancer.

Christopher L. Moertel, MD, discusses the management of MEK inhibitor–associated toxicities in NF1-associated plexiform neurofibromas.

Julie M. Vose, MD, MBA, discusses the optimal use of epcoritamab for select patients with relapsed/refractory large B-cell lymphoma.

Benjamin Herzberg, MD, discusses current and future research efforts in KRAS-mutated NSCLC.

Frozen section analysis may be better reserved for high-risk tumor resections, as routine use shows limited benefit and increases cost, survey suggests.

Joan Carles Galceran, MD, PhD, discusses the safety of adding darolutamide to ADT and docetaxel in older patients with mHSPC.

Axel Merseburger, MD, PhD, discusses AEs associated with real-world treatment discontinuations of avelumab plus axitinib in advanced renal cell carcinoma.

Scott Kopetz, MD, PhD, FACP, discusses the safety of encorafenib plus cetuximab with/without chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

Michael J. Morris, MD, discusses the FD expanded approval of lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with PSMA-positive mCRPC.

Jennifer Chan, MD, MPH, discusses the prevalence of neuroendocrine tumors during Adolescent and Young Adult Cancer Awareness Week.

Tanya B. Dorff, MD, highlights the safety profile of lutetium Lu 177 vipivotide tetraxetan in patients with mCRPC with impaired renal function.

Tanya Gupta, MD, shares factors informing frontline treatment approaches for metastatic hormone receptor–positive, HER2-negative breast cancer.

Andreas M. Kaiser, MD, discusses the benefits of minimally invasive surgery for patients with colorectal cancer.

María-Victoria Mateos, MD, PhD, discusses long-term OS data from the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

Ioannis Politikos, MD, discusses data from a study which compared the immune reconstitution profiles of Orca-T with those from CD34 allograft recipients.

Yong Jae Lee, MD, PhD, discusses key efficacy outcomes with nivolumab monotherapy in completely surgically resectable dMMR endometrial cancer.

Alexander B. Olawaiye, MD, discusses future research that could inform the use of afuresertib plus paclitaxel in platinum-resistant ovarian cancer.

Melissa M. Hardesty, MD, discusses OS and subgroup data from the OVARIO study of niraparib and bevacizumab maintenance in newly diagnosed ovarian cancer.

Linda R. Duska, MD, MPH, discusses OS and PFS2 outcomes with concurrent pembrolizumab and chemoradiotherapy in high-risk advanced cervical cancer.

Olalekan O. Oluwole, MD, MPH, details the importance of early intervention regarding adverse effects following CAR T products in relapsed/refractory LBCL.

Dr Bowman discusses immune-related and TKI-specific toxicities when combining immunotherapy and TKIs in non–clear cell RCC.

Juan P. Alderuccio, MD, discusses data from loxcastuximab tesirine plus rituximab in high-risk, relapsed/refractory follicular lymphoma.

Juan Carlos Hernández-Boluda, MD, PhD, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk in myelofibrosis.

Tashanna K. Myers, MD, discusses HRQOL findings in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine in MIRASOL.

Chunyan Lan, MD, PhD, discusses data with cadonilimab plus lenvatinib in advanced endometrial cancer, as well as next steps for evaluating the combination.

Matthew Galsky, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy for patients with muscle-invasive bladder cancer.

Georges Ayoub, MD, MS, discusses how a supervised deep-learning model trained with expert-labeled data seeks to improve interpretability and diagnostic precision in glioblastoma morphological analysis.

Gao-Jun Teng, MD, contextualizes efficacy data with TACE plus camrelizumab and rivoceranib in HCC from the phase 2 CARES-005 trial.